Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Novo Nordisk on Friday reported strong early-stage results for its once-a-week obesity drug. Before the open, Novo Nordisk stock jumped while Eli Lilly fell. In the phase 1b/2a clinical trial, obese ...

Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Novo Nordisk's experimental obesity drug amycretin demonstrated promising weight loss results in an early-stage trial, with participants losing 22% of their body weight in 36 weeks. This news boosted ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

The healthcare industry experienced a rollercoaster of a year in 2024, with pharmacy benefits undergoing significant shifts.

A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...

The trial tested amycretin in its injectable form, but Novo Nordisk is also separately developing the drug in pill form. Investors cheered an early trial of the pill early last year that showed weight ...

We recently published a list of 10 Best Falling Stocks to Invest in Right Now. In this article, we are going to take a look ...

Novo Nordisk's experimental obesity drug, amycretin, displayed impressive results, causing a 22% weight loss in participants over 36 weeks. The news boosted Novo’s shares and highlights its potential ...